Andy Tompkins, MD, MHS

Title(s)Professor, Psychiatry
SchoolSchool of Medicine
Address995 Potrero Avenue, #511
San Francisco CA 94110
Phone628-206-3645
ORCID ORCID Icon0000-0002-2112-2299 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Emory University, Atlanta, GABS05/1999Biology / English
    New York Medical College, Valhalla, NYMD05/2004Medicine
    Johns Hopkins Bayview Medical Center, Baltimore, MDInternship06/2005Psychiatry-Medicine
    Johns Hopkins Hospital, Baltimore, MDResidency06/2008Psychiatry
    Johns Hopkins University School of Medicine, Baltimore, MDPost-doctoral Fellowship06/2010Behavioral Pharmacology / Addictions
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MDMHS08/2014Clinical Investigation

    Collapse Overview 
    Collapse webpage
    Collapse media links

    Collapse Research 
    Collapse research activities and funding
    Project JUNO Community (JUstice-iNvolved Opioid use disorder treatment engagement in Community)
    SAMHSA H79TI084269Sep 29, 2021 - Sep 29, 2026
    Role: Executive Director / PI
    The Effect of Chronic Pain on Delay Discounting in Methadone Patients
    NIH R21DA047520Sep 30, 2019 - Aug 31, 2021
    Role: Principal Investigator
    Project HOUDINI LINK: Hospital Opioid Use Disorder treatment Initiation and LINKage to care
    SAMHSA H79TI081419-01Sep 30, 2018 - Sep 29, 2021
    Role: Executive Director / PI
    Improving the Opioid Treatment Outpatient Program (OTOP) through the Addition of Yoga Therapy
    San Francisco General Hospital Foundation 34843Jul 1, 2018 - Jun 30, 2019
    Role: Principal Investigator
    Opioid and cannabinoid combinations in laboratory and clinical pain
    NIH R01DA042751May 15, 2017 - Apr 30, 2020
    Role: Co-Investigator
    Using Cannabinoids to Enhance Opioid Analgesic Effects in Humans
    NIH R01DA040644Aug 1, 2016 - Jun 30, 2021
    Role: Co-Investigator
    Role of Sleep in the Treatment of Cannabis Dependence
    NIH U01DA031784Jul 1, 2012 - Jun 30, 2017
    Role: Co-Investigator
    Optimizing Pain Treatment while Reducing Abuse Liability in Opioid Dependence
    NIH K23DA029609Jul 1, 2012 - May 31, 2017
    Role: Principal Investigator
    Mechanisms of Sleep Disruption Hyperalgesia
    NIH R01DA032922Jun 1, 2012 - Aug 31, 2018
    Role: Co-Investigator
    Multisite Controlled Trial of Cocaine Vaccine (3 of 6) Baltimore Treatment Site
    NIH R01DA025251Sep 15, 2008 - Jan 31, 2013
    Role: Co-Investigator
    Clinical Trial of Topiramate for Cocaine Addiction
    NIH R01DA021808Sep 20, 2006 - Jul 31, 2012
    Role: Co-Investigator
    Western States Node of the National Drug Abuse Treatment Clinical Trials Network
    NIH UG1DA015815Sep 30, 2002 - Feb 28, 2025
    Role: Site PI
    Description: I am the site PI of CTN-0080, Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs.
    Human Behavioral Pharmacology of Substance Abuse
    NIH 2T32DA007209-26Feb 1, 1981 - Jun 30, 2011
    Role: Post-doctoral Fellow
    Human Behavioral Pharmacology of Substance Abuse
    NIH 5T32DA007209-27Feb 1, 1981 - Jun 30, 2011
    Role: Post-doctoral Fellow

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis. Alcohol Clin Exp Res (Hoboken). 2025 Jan; 49(1):244-255. Luk JW, Ha NB, Shui AM, Snyder HR, Batki SL, Ostacher MJ, Monto A, Wong RJ, Cheung R, Parekh P, Hua W, Tompkins DA, Fakadej T, Haight CG, Liao M, Khalili M, Satre DD. PMID: 39632077; PMCID: PMC11747812.
      View in: PubMed   Mentions: 3     Fields:    
    2. Induction to Methadone 80 mg in the First Week of Treatment of Patients Who Use Fentanyl: A Case Series From an Outpatient Opioid Treatment Program. J Addict Med. 2024 Sep-Oct 01; 18(5):580-585. Steiger S, McCuistian C, Suen LW, Shapiro B, Tompkins DA, Bazazi AR. PMID: 39150067; PMCID: PMC11446640.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder. J Subst Use Addict Treat. 2024 01; 156:209180. Lee DC, Schlienz NJ, Herrmann ES, Martin EL, Leoutsakos J, Budney AJ, Smith MT, Tompkins DA, Hampson AJ, Vandrey R. PMID: 37802317; PMCID: PMC12080489.
      View in: PubMed   Mentions: 1     Fields:    
    4. Substance Use in the Performing Artist with Chronic Pain. Med Probl Perform Art. 2022 Mar; 37(1):24-29. Hay KR, Jardot J, Huhn AS, Tompkins DA. PMID: 35234802; PMCID: PMC9795469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. "I got a bunch of weed to help me through the withdrawals": Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. PLoS One. 2022; 17(2):e0263583. Meacham MC, Nobles AL, Tompkins DA, Thrul J. PMID: 35134074; PMCID: PMC8824349.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    6. Assessing the Acceptability of Yoga Among Patients with and without Chronic Pain Enrolled in a Licensed Opioid Treatment Program. Int J Yoga Therap. 2022 Jan 01; 32(2022). Ahmadi E, Evans C, Agin-Liebes G, Tompkins DA. PMID: 35377949; PMCID: PMC9799967.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. A Qualitative Investigation Into Faith and LGBTQ Identities in a Nonclinical Sample of Readers of the Dear Abby Column: The Dear Abby Project. J Nerv Ment Dis. 2021 Dec 01; 209(12):855-858. Ghazzawi A, Casoy F, Libby N, McIntosh C, Barber M, Adelson S, Ahola J, Ashley K, Chavez AM, Erickson-Schroth L, Fadus M, Goldenberg D, Hung K, Lothwell L, Mattson M, McAfee SG, Nowaskie DZ, Schwartz A, Tompkins DA, Yarbrough ER, Drescher J. PMID: 34846354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status. Drug Alcohol Depend. 2021 11 01; 228:109092. Pro G, Tompkins DA, Azari S, Zaller N. PMID: 34571287.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    9. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. Drug Alcohol Depend. 2021 09 01; 226:108869. Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA. PMID: 34216862; PMCID: PMC9559787.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Experimental sleep disruption attenuates morphine analgesia: findings from a randomized trial and implications for the opioid abuse epidemic. Sci Rep. 2020 11 18; 10(1):20121. Smith MT, Mun CJ, Remeniuk B, Finan PH, Campbell CM, Buenaver LF, Robinson M, Fulton B, Tompkins DA, Tremblay JM, Strain EC, Irwin MR. PMID: 33208831; PMCID: PMC7674501.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    11. Religious faith and transgender identities: The Dear Abby project. Journal of Gay & Lesbian Mental Health. 2020; 24(2):190-204. Alhasan Ghazzawi, Selena Suhail-Sindhu, Flávio Casoy, Naomi Libby, Christopher A. McIntosh, Stewart Adelson, Kenneth Ashley, Jack Drescher, David Goldenberg, Kenneth Hung, Lorraine E. Lothwell, Marlin R. Mattson, Scot G. McAfee, Alan Schwartz, D. Andrew Tompkins, Eric Yarbrough & Mary E. Barber . View Publication.
    12. Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal. Pain Med. 2019 10 01; 20(10):1942-1947. Huhn AS, Tompkins DA, Campbell CM, Dunn KE. PMID: 30690594; PMCID: PMC6784741.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    13. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. Drug Alcohol Depend. 2019 09 01; 202:111-114. Bergeria CL, Huhn AS, Tompkins DA, Bigelow GE, Strain EC, Dunn KE. PMID: 31336328; PMCID: PMC6745696.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use. J Addict Med. 2019 Jul/Aug; 13(4):300-305. Hay KR, Huhn AS, Tompkins DA, Dunn KE. PMID: 30633045; PMCID: PMC6609500.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. Sex differences in measures of central sensitization and pain sensitivity to experimental sleep disruption: implications for sex differences in chronic pain. Sleep. 2019 02 01; 42(2). Smith MT, Remeniuk B, Finan PH, Speed TJ, Tompkins DA, Robinson M, Gonzalez K, Bjurstrom MF, Irwin MR. PMID: 30371854; PMCID: PMC6369729.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    16. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. Anesthesiology. 2019 01; 130(1):131-141. Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Tompkins DA. PMID: 30418214; PMCID: PMC6295244.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients. Neuropsychopharmacology. 2019 03; 44(4):826-833. Huhn AS, Sweeney MM, Brooner RK, Kidorf MS, Tompkins DA, Ayaz H, Dunn KE. PMID: 30375498; PMCID: PMC6372589.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    18. Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Streel. Addiction. 2019 01; 114(1):189-190. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow G, Silverman K. PMID: 30345640.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018 12 01; 193:142-147. Huhn AS, Strain EC, Tompkins DA, Dunn KE. PMID: 30384321; PMCID: PMC6242338.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    20. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addict Biol. 2020 01; 25(1):e12680. Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, Strain EC. PMID: 30295400; PMCID: PMC6546557.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    21. Psychiatric Disorders and Comorbid Cannabis Use: When Should We Be Concerned and What Can We Do About It? J Clin Psychiatry. 2018 09 11; 79(6). Satre DD, Borsari B, Tompkins DA, Ramo D. PMID: 30256546.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug Alcohol Depend. 2018 06 01; 187:171-178. Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. PMID: 29674251.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    23. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018 07; 113(7):1188-1209. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. PMID: 29396985; PMCID: PMC5993595.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    24. Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply. JAMA Psychiatry. 2018 02 01; 75(2):215. Dunn KE, Tompkins DA, Strain EC. PMID: 29282473.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 11 01; 180:279-285. Huhn AS, Tompkins DA, Dunn KE. PMID: 28942031; PMCID: PMC5648596.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    26. Ethnic Differences in the Effects of Naloxone on Sustained Evoked Pain: A Preliminary Study. Divers Equal Health Care. 2017; 14(5):236-242. Burton EF, Suen SY, Walker JL, Bruehl S, Peterlin BL, Tompkins DA, Buenaver LF, Edwards RR, Campbell CM. PMID: 30984393; PMCID: PMC6461381.
      View in: PubMed   Mentions: 2  
    27. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry. 2017 09 01; 74(9):885-893. Dunn KE, Tompkins DA, Bigelow GE, Strain EC. PMID: 28700791; PMCID: PMC5710234.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    28. To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self-identified chronic pain patients. Addiction. 2018 Jan; 113(1):67-79. Tompkins DA, Huhn AS, Johnson PS, Smith MT, Strain EC, Edwards RR, Johnson MW. PMID: 28645137; PMCID: PMC5725253.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Providing chronic pain management in the "Fifth Vital Sign" Era: Historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend. 2017 Apr 01; 173 Suppl 1:S11-S21. Tompkins DA, Hobelmann JG, Compton P. PMID: 28363315; PMCID: PMC5771233.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    30. Pain catastrophizing may moderate the association between pain and secondary hyperalgesia. J Appl Biobehav Res. 2017 Mar; 22(1). Pressman AJ, Peterlin BL, Tompkins DA, Salas RE, Buenaver LF, Haythornthwaite JA, Campbell CM. PMID: 30983846; PMCID: PMC6461383.
      View in: PubMed   Mentions: 8  
    31. Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. Pain. 2016 08; 157(8):1724-1732. Tompkins DA, Johnson PS, Smith MT, Strain EC, Edwards RR, Johnson MW. PMID: 27075431; PMCID: PMC4949122.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    32. The Growing Regulation of Conversion Therapy. J Med Regul. 2016; 102(2):7-12. Drescher J, Schwartz A, Casoy F, McIntosh CA, Hurley B, Ashley K, Barber M, Goldenberg D, Herbert SE, Lothwell LE, Mattson MR, McAfee SG, Pula J, Rosario V, Tompkins DA. PMID: 27754500; PMCID: PMC5040471.
      View in: PubMed   Mentions: 16  
    33. Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis. Addict Disord Their Treat. 2015 Dec; 14(4):211-219. Tompkins DA, Sides JA, Harrison JA, Strain EC. PMID: 26752979; PMCID: PMC4704795.
      View in: PubMed   Mentions: 3  
    34. Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. Drug Alcohol Depend. 2015 Dec 01; 157:143-9. Dunn KE, Finan PH, Tompkins DA, Fingerhood M, Strain EC. PMID: 26518253; PMCID: PMC4663104.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    35. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014 Oct; 135(1):163-71. Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. PMID: 25072931; PMCID: PMC4404750.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    36. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014 Jul 01; 140:92-100. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE. PMID: 24814607; PMCID: PMC4431633.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    37. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul 01; 140:42-7. Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K. PMID: 24793366; PMCID: PMC4073297.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansPHPublic Health
    38. The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. Clin J Pain. 2014 Jan; 30(1):36-45. Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC. PMID: 23446076; PMCID: PMC3676462.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2014 Feb; 348(2):217-26. Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. PMID: 24227768; PMCID: PMC3912547.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    40. Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):369-72. Antoine DG, Strain EC, Tompkins DA, Bigelow GE. PMID: 23369645; PMCID: PMC3911782.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. Report of the American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. Arch Sex Behav. 2012 Aug; 41(4):759-96. Byne W, Bradley SJ, Coleman E, Eyler AE, Green R, Menvielle EJ, Meyer-Bahlburg HF, Pleak RR, Tompkins DA, American Psychiatric Association Task Force on Treatment of Gender Identity Disorder. PMID: 22736225.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    42. Treatment of gender identity disorder. Am J Psychiatry. 2012 Aug; 169(8):875-6. Byne W, Bradley SJ, Coleman E, Eyler AE, Green R, Menvielle E, Meyer-Bahlburg HF, Pleak RR, Tompkins DA. PMID: 22854940.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011 Apr; 15(2):129-36. Tompkins DA, Campbell CM. PMID: 21225380; PMCID: PMC3165032.
      View in: PubMed   Mentions: 38     Fields:    
    44. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl). 2010 Jul; 210(4):471-80. Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. PMID: 20386884; PMCID: PMC2878387.
      View in: PubMed   Mentions: 11     Fields:    
    45. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009 Nov 01; 105(1-2):154-9. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. PMID: 19647958; PMCID: PMC2774236.
      View in: PubMed   Mentions: 65     Fields:    
    46. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005 Oct; 44(10):1024-31. Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, Nusser L, Kranzler H, Napolitano B, Frederickson A, Henderson I, Rhinewine J, Kumra S. PMID: 16175107.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    47. Phenotypic screening of mutations in Pmr1, the yeast secretory pathway Ca2+/Mn2+-ATPase, reveals residues critical for ion selectivity and transport. J Biol Chem. 2000 Aug 04; 275(31):23927-32. Wei Y, Chen J, Rosas G, Tompkins DA, Holt PA, Rao R. PMID: 10801855.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    Andy's Networks
    Concepts (199)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.